Antibodies as defensive enzymes
- PMID: 15633014
- DOI: 10.1007/s00281-004-0191-1
Antibodies as defensive enzymes
Abstract
Antibodies (Abs) and enzymes are structural and functional relatives. Abs with promiscuous peptidase activity are ubiquitous in healthy humans, evidently derived from germline variable domain immunoglobulin genes encoding the serine protease-like nucleophilic function. Exogenous and endogenous electrophilic antigens can bind the nucleophilic sites covalently, and recent evidence suggests that immunization with such antigens can induce proteolytic antibodies. Previously, Ab catalytic activities have been linked to pathogenic autoimmune reactions, but recent studies indicate that proteolytic Abs may also serve beneficial functions. An example is the rapid and selective cleavage of the HIV-1 coat protein gp120 by IgMs found in uninfected humans. The selectivity of this reaction appears to derive from recognition of gp120 as a superantigen. A second example is the cleavage of amyloid beta-peptide by IgM and IgG from aged humans, a phenomenon that may represent a specific proteolytic response to a neurotoxic endogenous peptide implicated in the pathogenesis of Alzheimer's disease.
Similar articles
-
Naturally occurring proteolytic antibodies: selective immunoglobulin M-catalyzed hydrolysis of HIV gp120.J Biol Chem. 2004 Sep 17;279(38):39611-9. doi: 10.1074/jbc.M406719200. Epub 2004 Jul 21. J Biol Chem. 2004. PMID: 15269209
-
Characterization of gp120 hydrolysis by IgA antibodies from humans without HIV infection.AIDS Res Hum Retroviruses. 2007 Dec;23(12):1541-54. doi: 10.1089/aid.2007.0081. AIDS Res Hum Retroviruses. 2007. PMID: 18160012
-
Innate antibody catalysis.Mol Immunol. 1999 Dec;36(18):1215-22. doi: 10.1016/s0161-5890(99)00141-8. Mol Immunol. 1999. PMID: 10684961
-
Prospects for immunotherapeutic proteolytic antibodies.J Immunol Methods. 2002 Nov 1;269(1-2):257-68. doi: 10.1016/s0022-1759(02)00236-3. J Immunol Methods. 2002. PMID: 12379366 Review.
-
Nucleophilic proteolytic antibodies.Appl Biochem Biotechnol. 2000 Jan-Mar;83(1-3):221-31; discussion 231-2, 297-313. doi: 10.1385/abab:83:1-3:221. Appl Biochem Biotechnol. 2000. PMID: 10826962 Review.
Cited by
-
Diminished amyloid-beta burden in Tg2576 mice following a prophylactic oral immunization with a salmonella-based amyloid-beta derivative vaccine.J Alzheimers Dis. 2009;18(4):961-72. doi: 10.3233/JAD-2009-1204. J Alzheimers Dis. 2009. PMID: 19749432 Free PMC article.
-
Plasma protein profiling of Mild Cognitive Impairment and Alzheimer's disease using iTRAQ quantitative proteomics.Proteome Sci. 2014 Jan 17;12(1):5. doi: 10.1186/1477-5956-12-5. Proteome Sci. 2014. PMID: 24433274 Free PMC article.
-
Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.J Alzheimers Dis. 2008 Oct;15(2):157-68. doi: 10.3233/jad-2008-15202. J Alzheimers Dis. 2008. PMID: 18953105 Free PMC article. Review.
-
Catalytic antibodies to HIV: physiological role and potential clinical utility.Autoimmun Rev. 2008 Jun;7(6):473-9. doi: 10.1016/j.autrev.2008.04.002. Epub 2008 Apr 29. Autoimmun Rev. 2008. PMID: 18558365 Free PMC article. Review.
-
Back to the future: covalent epitope-based HIV vaccine development.Expert Rev Vaccines. 2010 Sep;9(9):1027-43. doi: 10.1586/erv.10.77. Expert Rev Vaccines. 2010. PMID: 20822346 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources